148 related articles for article (PubMed ID: 20595378)
1. Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics.
Hippalgaonkar K; Srirangam R; Avula B; Khan IA; Majumdar S
Drug Metab Dispos; 2010 Oct; 38(10):1790-7. PubMed ID: 20595378
[TBL] [Abstract][Full Text] [Related]
2. Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.
Majumdar S; Hippalgaonkar K; Srirangam R
Drug Metab Dispos; 2009 Aug; 37(8):1718-25. PubMed ID: 19406953
[TBL] [Abstract][Full Text] [Related]
3. Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine.
Duvvuri S; Gandhi MD; Mitra AK
Curr Eye Res; 2003 Dec; 27(6):345-53. PubMed ID: 14704918
[TBL] [Abstract][Full Text] [Related]
4. Role of P-glycoprotein in distribution of rhodamine 123 into aqueous humor in rabbits.
Kajikawa T; Mishima HK; Murakami T; Takano M
Curr Eye Res; 1999 Mar; 18(3):240-6. PubMed ID: 10342379
[TBL] [Abstract][Full Text] [Related]
5. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study.
Maeda K; Takano J; Ikeda Y; Fujita T; Oyama Y; Nozawa K; Kumagai Y; Sugiyama Y
Clin Pharmacol Ther; 2011 Aug; 90(2):263-70. PubMed ID: 21716273
[TBL] [Abstract][Full Text] [Related]
6. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
Dagenais C; Zong J; Ducharme J; Pollack GM
Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption.
Dey S; Gunda S; Mitra AK
J Pharmacol Exp Ther; 2004 Oct; 311(1):246-55. PubMed ID: 15175422
[TBL] [Abstract][Full Text] [Related]
8. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
Mendell J; Zahir H; Matsushima N; Noveck R; Lee F; Chen S; Zhang G; Shi M
Am J Cardiovasc Drugs; 2013 Oct; 13(5):331-42. PubMed ID: 23784266
[TBL] [Abstract][Full Text] [Related]
9. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
10. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
11. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization.
Jain R; Majumdar S; Nashed Y; Pal D; Mitra AK
Mol Pharm; 2004; 1(4):290-9. PubMed ID: 15981588
[TBL] [Abstract][Full Text] [Related]
12. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.
Westerhout J; Smeets J; Danhof M; de Lange EC
J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):327-42. PubMed ID: 23539188
[TBL] [Abstract][Full Text] [Related]
13. Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats.
Piao YJ; Li X; Choi JS
Eur J Drug Metab Pharmacokinet; 2008; 33(3):159-64. PubMed ID: 19007041
[TBL] [Abstract][Full Text] [Related]
14. Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate.
Syvänen S; Schenke M; van den Berg DJ; Voskuyl RA; de Lange EC
AAPS J; 2012 Mar; 14(1):87-96. PubMed ID: 22215264
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor activation induces P-glycoprotein and increases brain efflux of quinidine: an intracerebral microdialysis study in conscious rats.
Durk MR; Fan J; Sun H; Yang Y; Pang H; Pang KS; de Lannoy IA
Pharm Res; 2015 Mar; 32(3):1128-40. PubMed ID: 25319098
[TBL] [Abstract][Full Text] [Related]
16. Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits.
Siegner SW; Giovanoni RL; Erickson KA; Netland PA
J Ocul Pharmacol Ther; 1998 Apr; 14(2):159-68. PubMed ID: 9572542
[TBL] [Abstract][Full Text] [Related]
17. Diurnal variation in P-glycoprotein-mediated transport and cerebrospinal fluid turnover in the brain.
Kervezee L; Hartman R; van den Berg DJ; Shimizu S; Emoto-Yamamoto Y; Meijer JH; de Lange EC
AAPS J; 2014 Sep; 16(5):1029-37. PubMed ID: 24917180
[TBL] [Abstract][Full Text] [Related]
18. Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition.
Yamazaki S; Evers R; De Zwart L
CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):55-67. PubMed ID: 34668334
[TBL] [Abstract][Full Text] [Related]
19. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
Kharasch ED; Hoffer C; Whittington D
Br J Clin Pharmacol; 2004 May; 57(5):600-10. PubMed ID: 15089813
[TBL] [Abstract][Full Text] [Related]
20. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
